Citations

Showing 10 of 108094 citations.

Migraine and Posttraumatic Headache: Similarities and Differences in Brain Network Connectivity
Chong, Catherine D. , Nikolova, Jennifer, Dumkrieger, Gina M, Chong, Catherine D , Dumkrieger, Gina

Mayo Clinic

Seminars in Neurology | November 2, 2022 | Volume: 42 | Issue: 04 | Pages: 441-448

10.1055/s-0042-1757929 | PMID 36323298 Get It

AbstractPosttraumatic headache (PTH) is the most common symptom following mild traumatic brain injury (mTBI) (also known as concussion). Migraine and PTH have similar phenotypes, and a migraine-like phenotype is common in PTH. The similarities between both headache types are intriguing and challenge a better understanding of the pathophysiological commonalities involved in migraine and PTH due to mTBI. Here, we review the PTH resting-state functional connectivity literature and compare it to migraine to assess overlap and differences in brain network function between both headache types. Migraine and PTH due to mTBI have overlapping and disease-specific widespread alterations of static and dynamic functional networks involved in pain processing as well as dysfunctional network connections between frontal regions and areas of pain modulation and pain inhibition. Although the PTH functional network literature is still limited, there is some evidence that dysregulation of the top-down pain control system underlies both migraine and PTH. However, disease-specific differences in the functional circuitry are observed as well, which may reflect unique differences in brain architecture and pathophysiology underlying both headache disorders.
Acute Treatment of Headache (Focus on Migraine)
Chiang, Chia‐Chun , Singh, Rashmi B. Halker

Mayo Clinic

Seminars in Neurology | November 2, 2022 | Volume: 42 | Issue: 04 | Pages: 494-502

10.1055/s-0042-1757926 | PMID 36323302 Get It

AbstractAcute treatments for migraine and cluster headache are necessary to abort attacks, relieve pain and associated symptoms, and restore an individual's ability to function. Acute headache treatments consist of a variety of medication and nonmedication options. In this article, we discuss the approach to acute treatment of migraine and cluster headache. We summarize the level of evidence to support each acute medication class according to recent systematic reviews and meta-analyses, as well as guideline recommendations from the American Headache Society, American Academy of Neurology, and European Federation of Neurological Society.
Update on Headache
Ward, Thomas N., Green, A. Laine, Green, A. Laine

Mayo Clinic

Seminars in Neurology | November 2, 2022 | Volume: 42 | Issue: 04 | Pages: 404-405

10.1055/s-0042-1757575 | PMID 36323297 Get It

Dravet Syndrome
Wirrell, Elaine , Wirrell, Elaine C , Nickels, Katherine

Mayo Clinic

Neurology | November 2, 2022 | Volume: 100 | Issue: 4 | Pages: 171-173

10.1212/wnl.0000000000201531 | PMID 36323523 Get It

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia
Advani, Anjali S. , Moseley, Anna , O’Dwyer, Kristen M. , Wood, Brent L. , Park, Jae H. , Wieduwilt, Matthew J. , Jeyakumar, Deepa , Yaghmour, George , Gerds, Aaron T. , Litzow, Mark R. , Stone, Richard M. , Gerds, Aaron T , Litzow, Mark R. , Sharon, Elad , Erba, Harry Paul , Advani, Anjali S , Wood, Brent L , O'Dwyer, Kristin , Atallah, Ehab , O’Brien, Susan , Liesveld, Jane L. , Othus, Megan , Sharon, Elad

Mayo Clinic

Blood Advances | November 2, 2022 | Volume: 7 | Issue: 7 | Pages: 1279-1285

10.1182/bloodadvances.2022008216 | PMID 36322825 Get It

Abstract Novel treatment strategies are needed for the treatment of Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) in older patients. This trial evaluated the feasibility and outcomes with the anti-CD19 bispecific T-cell–engaging antibody, blinatumomab, in combination with dasatinib and steroids. Patients 65 years of age or older with Ph+ or Ph-like ALL (with dasatinib-sensitive fusions/mutations) were eligible and could be newly diagnosed or relapsed/refractory. Induction therapy consisted of dasatinib/prednisone. Patients not achieving response by day 56 proceeded to blinatumomab reinduction therapy. Patients achieving response with induction or reinduction therapy proceeded to blinatumomab/dasatinib postremission therapy for 3 cycles followed by dasatinib/prednisone maintenance. All patients received central nervous system prophylaxis with intrathecal methotrexate for a total of 8 doses. Response was assessed at days 28, 56, and 84 and at additional time points based on response parameters. Measurable residual disease was assessed centrally by 8-color flow cytometry at day 28. A total of 24 eligible patients with newly diagnosed Ph+ ALL were enrolled with a median age of 73 years (range, 65-87 years). This combination was safe and feasible. With a median of 2.7 years of follow-up, 3-year overall survival and disease-free survival were 87% (95% confidence interval [CI], 64-96) and 77% (95% CI, 54-90), respectively. Although longer follow-up is needed, these results are encouraging, and future trials are building on this backbone regimen. This trial was registered at www.clinicaltrials.gov as #NCT02143414.
Cost-effectiveness of 10-kHz spinal cord stimulation therapy compared with conventional medical management over the first 12 months of therapy for patients with nonsurgical back pain: randomized controlled trial
Lad, Shivanand P. , Jameson, Jessica , Kosek, Peter, Waldorff, Erik I. , Shum, Laura C. , Province‐Azalde, Rose , Patel, Naresh P. , Wu, Chengyuan , Sayed, Dawood , Kapural, Leonardo

Mayo Clinic

Journal of Neurosurgery: Spine | November 2, 2022 | Volume: 38 | Issue: 2 | Pages: 249-257

10.3171/2022.9.spine22416 | PMID 36272125 Get It

OBJECTIVE This analysis evaluated if spinal cord stimulation (SCS) at 10 kHz plus conventional medical management (CMM) is cost-effective compared with CMM alone for the treatment of nonsurgical refractory back pain (NSRBP). METHODS NSRBP subjects were randomized 1:1 into the 10-kHz SCS (n = 83) or CMM (n = 76) group. Outcomes assessed at 6 months included EQ-5D 5-level (EQ-5D-5L), medication usage, and healthcare utilization (HCU). There was an optional crossover at 6 months and follow-up to 12 months. The incremental cost-effectiveness ratio (ICER) was calculated with cost including all HCU and medications except for the initial device and implant procedure, and cost-effectiveness was analyzed based on a willingness-to-pay threshold of < $50,000 per quality-adjusted life-year. RESULTS Treatment with 10-kHz SCS resulted in a significant improvement in quality of life (QOL) over CMM (EQ-5D-5L index score change of 0.201 vs −0.042, p < 0.001) at a lower cost, based on reduced frequency of HCU resulting in an ICER of −$4964 at 12 months. The ICER was −$8620 comparing the 6 months on CMM with postcrossover on 10-kHz SCS. CONCLUSIONS Treatment with 10-kHz SCS provides higher QOL at a lower average cost per patient compared with CMM. Assuming an average reimbursement for device and procedure, 10-kHz SCS therapy is predicted to be cost-effective for the treatment of NSRBP compared with CMM within 2.1 years.
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma
Castellino, Sharon M. , Pei, Qinglin , Parsons, Susan K. , McCarten, Kathleen M. , Cho, Steve , Wu, Yue , Punnett, Angela , Henderson, Tara O. , Charpentier, Anne-Marie , Keller, Frank G. , Kelly, Kara M. , McCarten, Kathleen, Horton, Terzah, Dave, Hema, K Parsons, Susan , Castellino, Sharon , Hodgson, David , Horton, Terzah M. , Dave, Hema , Hoppe, Bradford S.

Mayo Clinic

New England Journal of Medicine | November 2, 2022 | Volume: 387 | Issue: 18 | Pages: 1649-1660

10.1056/nejmoa2206660 | PMID 36322844 Get It

Transcription factor FoxM1 promotes cyst growth in PKD1 mutant ADPKD
Yu, Wenyan , Wang, Guojuan , Li, Xiaoyan , Zhang, Hongbing , Gui, Xuehong, Zhou, Julie , Calvet, James P. , Li, Linda Xiaoyan , Zhou, Julie Xia, Li, Xiaogang , Li, Xiaogang

Mayo Clinic

Human Molecular Genetics | November 2, 2022 | Volume: 32 | Issue: 7 | Pages: 1114-1126

10.1093/hmg/ddac273 | PMID 36322156 Get It

AbstractAutosomal dominant polycystic kidney disease (ADPKD) is driven by mutations in the PKD1 and PKD2 genes, and it is characterized by renal cyst formation, inflammation and fibrosis. Forkhead box protein M1 (FoxM1), a transcription factor of the Forkhead box (Fox) protein super family, has been reported to promote tumor formation, inflammation and fibrosis in many organs. However, the role and mechanism of FoxM1 in regulation of ADPKD progression is still poorly understood. Here, we show that FoxM1 is an important regulator of cyst growth in ADPKD. FoxM1 is upregulated in cyst-lining epithelial cells in Pkd1 mutant mouse kidneys and human ADPKD kidneys. FoxM1 promotes cystic renal epithelial cell proliferation by increasing the expression of Akt and Stat3 and the activation of ERK and Rb. FoxM1 also regulates cystic renal epithelial cell apoptosis through NF-κB signaling pathways. In addition, FoxM1 regulates the recruitment and retention of macrophages in Pkd1 mutant mouse kidneys, a process that is associated with FoxM1-mediated upregulation of monocyte chemotactic protein 1. Targeting FoxM1 with its specific inhibitor, FDI-6, delays cyst growth in rapidly progressing and slowly progressing Pkd1 mutant mouse kidneys. This study suggests that FoxM1 is a central and upstream regulator of ADPKD pathogenesis and provides a rationale for targeting FoxM1 as a therapeutic strategy for ADPKD treatment.
Turning on the light for brain tumor surgery: A 5-aminolevulinic acid story
McCracken, David , Schüpper, Alexander J. , Lakomkin, Nikita , Malcolm, James G. , Bray, David P. , Hadjipanayis, Costas G. , Hadjipanayis, Constantinos G , McCracken, David J

Mayo Clinic

Neuro-Oncology | November 2, 2022 | Volume: 24 | Issue: Supplement_6 | Pages: S52-S61

10.1093/neuonc/noac191 | PMID 36322101 Get It

Abstract To aid surgeons in more complete and safe resection of brain tumors, adjuvant technologies have been developed to improve visualization of target tissue. Fluorescence-guided surgery relies on the use of fluorophores and specific light wavelengths to better delineate tumor tissue, inflammation, and areas of blood–brain barrier breakdown. 5-aminolevulinic acid (5-ALA), the first fluorophore developed specifically for brain tumors, accumulates within tumor cells, improving visualization of tumors both at the core, and infiltrative margin. Here, we describe the background of how 5-ALA integrated into the modern neurosurgery practice, clinical evidence for the current use of 5-ALA, and future directions for its role in neurosurgical oncology. Maximal safe resection remains the standard of care for most brain tumors. Gross total resection of high-grade gliomas (HGGs) is associated with greater overall survival and progression-free survival (PFS) in comparison to subtotal resection or adjuvant treatment therapies alone.1–3 A major challenge neurosurgeons encounter when resecting infiltrative gliomas is identification of the glioma tumor margin to perform a radical resection while avoiding and preserving eloquent regions of the brain. 5-aminolevulinic acid (5-ALA) remains the only optical-imaging agent approved by the FDA for use in glioma surgery and identification of tumor tissue.4 A multicenter randomized, controlled trial revealed that 5-ALA fluorescence-guided surgery (FGS) almost doubled the extent of tumor resection and also improved 6-month PFS.5 In this review, we will highlight the current evidence for use of 5-ALA FGS in brain tumor surgery, as well as discuss the future directions for its use.
Excerno: Using Mutational Signatures in Sequencing Data to Filter False Variants Caused by Clinical Archival
Mitchell, Audrey, Ruiz, Marco, Yang, Soua, Davila, Jaime , Davila, Jaime I , Wang, Chen

Mayo Clinic

Journal of Computational Biology | November 2, 2022 | Volume: 30 | Issue: 4 | Pages: 366-375

10.1089/cmb.2022.0394 | PMID 36322906 Get It

The accurate detection of point mutations from pathology slides using sequencing data is of great importance in cancer genomics and precision oncology. Formalin-fixation paraffin-embedding (FFPE) is a widely used technique to preserve pathology tissues. The FFPE process introduces artificial C > T mutations in next-generation sequencing, so we set out to develop excerno , a method to score and filter such spurious variants. FFPE mutational artifacts follow a mutational signature. By using the FFPE signature and Bayes' formula, we can calculate the probability of a mutation resulting from the FFPE process and use this probability to filter FFPE variants. We implement this method as the excerno R package. We tested excerno by simulating mutations across all 60-baseline mutational signatures from the Catalog of Somatic Mutations in Cancer (COSMIC) and combining them with mutations following the FFPE mutational signature. The sensitivity and specificity of excerno are adversely affected by the cosine similarity between the baseline and FFPE signatures ( c o s F F P E ). Higher percentages of FFPE mutations ( p c t F F P E ) result in increased sensitivity and reduced specificity. The specificity and sensitivity of excerno can be predicted as linear model with an interaction term using c o s F F P E and p c t F F P E , with an R 2 o f 0 . 8 4 and 0.79, respectively. Finally, we tested excerno using six RNA sequencing cancer samples and observed concordant trends of specificity and sensitivity with respect to our simulated data. The excerno R package can be used to annotate and filter FFPE-induced mutations in cancer genomics. Our method is adversely affected by c o s F F P E and p c t F F P E .